Trelegy Ellipta

RSS

fluticasone furoate / umeclidinium / vilanterol

Authorised
This medicine is authorised for use in the European Union.

Overview

Trelegy Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Trelegy Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a long-acting muscarinic antagonist. Long-acting beta-2 agonists widen the airways; corticosteroids reduce inflammation in the airways and lungs; and muscarinic receptor antagonists cause the muscles of the airways to relax.

Trelegy Ellipta is used for maintenance (regular) treatment on a daily basis. It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.

This EPAR was last updated on 25/07/2022

Authorisation details

Product details
Name
Trelegy Ellipta
Agency product number
EMEA/H/C/004363
Active substance
  • fluticasone furoate
  • umeclidinium bromide
  • vilanterol trifenatate
International non-proprietary name (INN) or common name
  • fluticasone furoate
  • umeclidinium
  • vilanterol
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
R03AL08
Publication details
Marketing-authorisation holder
GlaxoSmithKline Trading Services
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
15/11/2017
Contact address

12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland

Product information

15/07/2022 Trelegy Ellipta - EMEA/H/C/004363 - R/0023

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating
2 ratings
1 rating
1 rating
1 rating